Novo Nordisk signed a $1.3 billion deal for technology to make longer-lasting obesity shots
- Novo Nordisk 近 90 天出现 14 次
- 上一次：2 天前 · U.S. demand for Novo Nordisk’s weight loss drugs is so huge that the Danish central bank just doubled the nation’s entire growth forecast
发生了什么
The agreement gives Novo exclusive rights to Swedish startup Nanexa's drug-coating technology for up to 5 programs targeting obesity and diabetes
摘要按规则整理自下方来源原文